WO2002002148A3 - Dual recombinant gene therapy compositions and methods of use - Google Patents
Dual recombinant gene therapy compositions and methods of use Download PDFInfo
- Publication number
- WO2002002148A3 WO2002002148A3 PCT/US2001/021059 US0121059W WO0202148A3 WO 2002002148 A3 WO2002002148 A3 WO 2002002148A3 US 0121059 W US0121059 W US 0121059W WO 0202148 A3 WO0202148 A3 WO 0202148A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- gene therapy
- compositions
- therapy compositions
- recombinant gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002216751A AU2002216751A1 (en) | 2000-06-30 | 2001-06-28 | Dual recombinant gene therapy compositions and methods of use |
EP01984094A EP1294407A2 (en) | 2000-06-30 | 2001-06-28 | Dual recombinant gene therapy compositions and methods of use |
CA002412847A CA2412847A1 (en) | 2000-06-30 | 2001-06-28 | Dual recombinant gene therapy compositions and methods of use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60776600A | 2000-06-30 | 2000-06-30 | |
US09/607,766 | 2000-06-30 | ||
US82629101A | 2001-04-03 | 2001-04-03 | |
US09/826,291 | 2001-04-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002002148A2 WO2002002148A2 (en) | 2002-01-10 |
WO2002002148A3 true WO2002002148A3 (en) | 2002-10-17 |
Family
ID=27085582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/021059 WO2002002148A2 (en) | 2000-06-30 | 2001-06-28 | Dual recombinant gene therapy compositions and methods of use |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1294407A2 (en) |
AU (1) | AU2002216751A1 (en) |
CA (1) | CA2412847A1 (en) |
WO (1) | WO2002002148A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6753321B2 (en) | 2000-09-15 | 2004-06-22 | Genvec, Inc. | Method of modulating neovascularization |
US20020164310A1 (en) * | 2001-03-02 | 2002-11-07 | Mgvs Ltd. | Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension |
ES2222782B1 (en) * | 2002-09-13 | 2006-03-01 | Advanced In Vitro Cell Technoligies, S.L. | METHOD FOR OBTAINING A SINGULAR CELL MODEL CAPABLE OF PLAYING IN VITRO THE METABOLIC IDIOSINCRASIA OF HUMAN BEINGS. |
US20080081354A1 (en) * | 2006-10-02 | 2008-04-03 | Cardiac Pacemakers, Inc. | Devices, vectors and methods for inducible ischemia cardioprotection |
US9017661B2 (en) * | 2011-02-22 | 2015-04-28 | The Board Of Regents Of The University Of Texas System | Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes |
WO2019222455A1 (en) * | 2018-05-16 | 2019-11-21 | University Of Massachusetts | Perfusion-based delivery of recombinant aav vectors for expression of secreted proteins |
US11280884B2 (en) * | 2018-08-30 | 2022-03-22 | Photodigm Inc. | LIDAR instrument and method for operating a LIDAR instrument |
CA3142534A1 (en) * | 2019-07-19 | 2021-01-28 | University Of Florida Research Foundation, Incorporated | Aav cardiac gene therapy for cardiomyopathy in humans |
CA3165469A1 (en) * | 2019-12-20 | 2021-06-24 | Research Institute At Nationwide Children's Hospital | Optimized gene therapy for targeting muscle in muscle diseases |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994011506A1 (en) * | 1992-11-18 | 1994-05-26 | Arch Development Corporation | Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
WO1996026742A1 (en) * | 1995-02-28 | 1996-09-06 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
WO1998010071A1 (en) * | 1996-09-06 | 1998-03-12 | Technion Research & Development Co., Ltd. | Angiogenic factor and use thereof in treating cardiovascular disease |
WO1998050079A2 (en) * | 1997-05-06 | 1998-11-12 | The Regents Of The University Of California | Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes |
WO1999040945A2 (en) * | 1998-02-11 | 1999-08-19 | The Regents Of The University Of California | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery |
WO2000040740A2 (en) * | 1998-12-30 | 2000-07-13 | Crucell Holland B.V. | Gene therapy to promote angiogenesis |
WO2001049325A2 (en) * | 2000-01-07 | 2001-07-12 | Stichting Klinische Farmacologie Groningen | Gene therapy to promote angiogenesis and/or the treatment of heart failure |
-
2001
- 2001-06-28 WO PCT/US2001/021059 patent/WO2002002148A2/en not_active Application Discontinuation
- 2001-06-28 AU AU2002216751A patent/AU2002216751A1/en not_active Abandoned
- 2001-06-28 CA CA002412847A patent/CA2412847A1/en not_active Abandoned
- 2001-06-28 EP EP01984094A patent/EP1294407A2/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994011506A1 (en) * | 1992-11-18 | 1994-05-26 | Arch Development Corporation | Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
WO1996026742A1 (en) * | 1995-02-28 | 1996-09-06 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
WO1998010071A1 (en) * | 1996-09-06 | 1998-03-12 | Technion Research & Development Co., Ltd. | Angiogenic factor and use thereof in treating cardiovascular disease |
WO1998050079A2 (en) * | 1997-05-06 | 1998-11-12 | The Regents Of The University Of California | Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes |
WO1999040945A2 (en) * | 1998-02-11 | 1999-08-19 | The Regents Of The University Of California | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery |
WO2000040740A2 (en) * | 1998-12-30 | 2000-07-13 | Crucell Holland B.V. | Gene therapy to promote angiogenesis |
WO2001049325A2 (en) * | 2000-01-07 | 2001-07-12 | Stichting Klinische Farmacologie Groningen | Gene therapy to promote angiogenesis and/or the treatment of heart failure |
Non-Patent Citations (3)
Title |
---|
DULAK JOZEF ET AL: "Gene transfer of vascular endothelial growth factor and endothelial nitric oxide synthase - Implications for gene therapy in cardiovascular diseases", DIALOG BIOSIS PREVIEWS, XX, XX, vol. 51, no. 3, May 1999 (1999-05-01), pages 233 - 241, XP002138212 * |
PEPPER M S ET AL: "Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 2, no. 189, 15 December 1992 (1992-12-15), pages 824 - 831, XP002078851, ISSN: 0006-291X * |
YLA-HERTTUALA S S ET AL: "Cardiovascular gene therapy", LANCET, XX, XX, vol. 355, no. 9199, 15 January 2000 (2000-01-15), pages 213 - 222, XP004263017, ISSN: 0140-6736 * |
Also Published As
Publication number | Publication date |
---|---|
EP1294407A2 (en) | 2003-03-26 |
WO2002002148A2 (en) | 2002-01-10 |
AU2002216751A1 (en) | 2002-01-14 |
CA2412847A1 (en) | 2002-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004027019A3 (en) | Improved raav expression systems for genetic modification of specific capsid proteins | |
WO2005021579A3 (en) | Epo mimetic peptides and fusion proteins | |
MXPA02001878A (en) | Novel b74 molecules and uses therefor. | |
EP1484339A3 (en) | Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same | |
WO2001073059A3 (en) | 38692 and 21117: dual specificity phosphatase molecules and uses therefor | |
WO2000046246A8 (en) | Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease | |
GB9911683D0 (en) | Antigenic peptides | |
WO2006131749A3 (en) | Scaffold | |
WO2002002148A3 (en) | Dual recombinant gene therapy compositions and methods of use | |
HUP0100267A2 (en) | Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof | |
AU5776799A (en) | Modified hcv peptide vaccines | |
WO2002016591A3 (en) | Human transporter family members and uses thereof | |
DE69712907D1 (en) | IMMUNOGENIC TLP COMPOSITION | |
EP1233024A3 (en) | 25466, a human transporter family member and uses therefor | |
WO2001098355A3 (en) | Cgi-69 compositions and methods of use | |
WO2001002429A3 (en) | Angiopoietin-6 and uses thereof | |
WO2001092490A3 (en) | Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof | |
WO2001081413A3 (en) | Isolated human transporter proteins, nucleic acids and uses thereof | |
WO2002018439A3 (en) | 52991, a human transporter protein and uses therefor | |
EP1225182A3 (en) | Human phospholipid transporter | |
WO2001081412A3 (en) | Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof | |
WO2003035840A3 (en) | 69583 and 85924, novel human protein kinase family members and uses therefor | |
WO2003048188A3 (en) | 15603, a human ion channel family member | |
WO2003002720A3 (en) | 2150, a human protein kinase family member and uses therefor | |
WO2002024911A3 (en) | 63760, a novel human transporter and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2412847 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002216751 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001984094 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001984094 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001984094 Country of ref document: EP |